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and HLA-Identical Sibling Marrow Transplantation
for Chronic Myelogenous Leukemia
Edward A. Copelan,1 Pamela Ann Crilley,2 Jeffrey Szer,3 Anthony J. Dodds,4
Dustin Stevenson,5 Gary Phillips,6 Patrick Elder,7 Ian Nivison-Smith,4 Belinda R. Avalos,7
Sam Penza,7 David Topolsky,2 Ronald Sobecks,1 Matt Kalaycio,1 Brian J. Bolwell1Allogeneic hematopoietic stem cell transplantation (HSCT) is the only known curative therapy for chronic
myelogenous leukemia (CML). Failure, because of relapse or nonrelapse mortality (NRM), generally occurs
within 3 years of transplantation, but large studies with long-term follow-up are limited. We present mature
results in 335 patients with CML who underwent allogeneic bone marrow transplantation (BMT) from HLA-
identical siblings following busulfan and cyclophosphamide (BU/Cy2). Two hundred twenty-nine were in
chronic phase (CP) and 106 in accelerated or blastic phase at transplantation. Median follow-up exceeded
14 years. The estimated probability of 18-year leukemia-free survival (LFS) for CP patients was 55.6% and
for those beyond CP, 10.5%. Of 182 patients who survived leukemia-free at 3 years, the estimated probability
of LFS at 18 years was 61.9%. Late relapse (P 5 .039) and late NRM (P 5 .008) occurred at higher rates in
patients beyond CP at transplantation. There was no plateau in LFS.
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(HSCT) is the only proven curative therapy for
chronic myelogenous leukemia (CML). Results of
allogeneic transplantation in CML have been widely
published, but median follow-up in most studies is 3
years or less [1-4]. Few large studies with prolonged
follow-up after HSCT have been reported, and these
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6/j.bbmt.2009.03.013sources and histocompatibility of donor cells. These
studies report survival, but not leukemia-free survival
(LFS) [5,6], providing the potential for overestimates
of cure rates in CML, where patients may attain sus-
tained survival following relapse [7,8]. Further, a single
institutional study with prolonged follow-up reported
a 15-year estimated cumulative relapse rate of only 8%
for CML patients in chronic phase (CP) undergoing
transplantation [9], substantially lower than that de-
tected in studies with shorter follow-up [7,8,10].
We present the results of the most extended follow-
up of a large cohort of patients with CML who under-
went allogeneic bone marrow transplantation (BMT)
from human leukocyte antigen (HLA)-identical sibling
donors following busulfan and cyclophosphamide (Bu/
Cy2), the most commonly used preparative regimen
in this malignancy [11]. This report focuses on late
relapse and death in patients in whom transplantation
is commonly considered to have been successful,
those alive, and leukemia-free 3 years following trans-
plantation.METHODS
Patients
All adults with CML who underwent allogeneic
BMT from HLA-identical sibling donors following851
Table 1. Clinical Characteristics of 335 Study Patients
852 Biol Blood Marrow Transplant 15:851-855, 2009E. A. Copelan et al.Bu/Cy2 at 4 centers in the United States and 3 in Aus-
tralia, between March 1984 and December 1995, are
included. Informed consent was obtained using forms
approved by the institutional review board at each cen-
ter. Data were analyzed as of January 1, 2008. One
hundred fifteen patients were included in a report pub-
lished in 1992 with a median follow-up of 3 years [2].
Clinical Care
All patients received identical preparation with Bu
1 mg/kg orally 4 times daily for 4 days followed
by Cy 60 mg/kg intravenously on each of 2 days
(Bu/Cy2) as previously described [2]. Bu doses were
not adjusted to target plasma levels. BM from HLA-
identical siblings was used as the source of HSC in
every patient. Cyclosporine (CsA) or tacrolimus-based
regimens were given to prevent graft-versus-host dis-
ease (GVHD). Prevention and treatment of infections
and other supportive care measures were administered
according to institutional guidelines.
Statistical Methods
Kaplan-Meier, cumulative hazard, and hazard rates
were used to characterize overall survival (OS), relapse,
and LFS. Kaplan-Meier methods were also used to
assess the OS, relapse, and LFS for only those 182 sub-
jects who survived 3 years leukemia-free. The log-rank
test was used to compare CP, accelerated, and blastic
phase patients. Univariate Cox proportional hazard
regression was used to estimate the OS, relapse, and
LFS hazard ratios for the following covariates: a 10-
year increase in age, male versus female, disease phase
XP accelerated, and blastic), acute GVHD (aGVHD),
chronic GVHD (cGVHD), and interval from diagnosis
to transplantation that was log transformed to the ap-
propriate scale.
Smoothed hazard curves were generated by adjust-
ment of the cumulative hazard into a continuous
‘‘smoothed’’ curve and then taking the derivative
with respect to time. Multivariable Cox proportional
hazard regression was used to estimate OS, relapse,
and LFS hazard ratios. These same techniques were
also used on the subgroup of patients that survived 3
years without disease. All relapses were hematologic
or cytogenetic. Treatment of relapse was heteroge-
neous and varied over time and by institution. Primary
cause of death was defined according to a published
scheme [12]. Stata version 10.0 (Stata Corporation,
College Station, TX) was used to run all analyses.Age, median (range) in years 37 (18-58)
Sex, number (percentage) of females 152 (45.4)
Disease stage at transplant, number (%)
Chronic phase 229 (68.3)
Accelerated 62 (18.5)
Blastic 44 (13.1)
Interval from diagnosis to transplant
Median (range) in months 9 (1-210)RESULTS
Patient Characteristics
A total of 335 consecutive adults with CML who un-
derwent allogeneic HSCT from HLA-identical siblingdonors at 7 institutions (Ohio State 88, Hahnemann
64, St. Vincent’s 55, Wilford Hall 44, Cleveland Clinic
35, Alfred 33, and Royal Melbourne 16) were included
in this analysis. Two hundred twenty-nine individuals
were in CP, 62 in accelerated phase, and 44 in blastic
phase at the time of transplantation. Table 1 summarizes
the clinical characteristics of the study patients. Surviv-
ing patients were followed for a median of more than
14 years after transplantation.OS and LFS from the Time of Transplantation
The 3-year OS from the time of transplantation for
the entire group was 57.4% (95% confidence interval
[CI]: 51.9 to 62.5%); the estimated probability of
18-year survival was 43.9% (95% CI: 37.9%-49.8%).
The estimated 3- and 18-year LFS were 55.6% (95%
CI: 50.1%-60.8%) and 34.4% (95% CI: 28.4%-
40.5%). For chronic phase patients the OS at 3 years is
70.5% (95% CI: 64.1% - 76.0%) and 58.6% (95% CI
51.4%-65.1%) were estimated to survive at 18 years.
LFS for CP patients was 68.8% (95% CI: 62.3%-
74.4%) at 3 and 46.0% (95% CI: 38%-53.6%) at 18
years. For accelerated phase patients, 3-year OS and
LFS were each 37.9% (95% CI: 25.6%-50%); estimated
18-year OS was 21.0% (95% CI: 10.5%-33.9%) and es-
timated probability of 18 year LFS was 17.5% (95% CI:
8.2%-29.7%). The 3-year OS for blastic phase patients
was 15.9% (95% CI: 7.0%-28.0%), and 3-year LFS
13.6% (95% CI: 5.5%-25.4%); no blastic phase patients
were estimated to survive at 18 years. The estimated
probability that patients beyond CP at transplantation
would be leukemia-free survivors at 18 years is 10.5%
(95% CI: 5.2%-18.3%).Relapse
The hazard rate for relapse fell sharply each year
through year 5, and then remained low, but constant
from years 6 through 14 (Figure 1). Twenty-seven
(42.2%) of the 64 (hematologic or persistent cytoge-
netic) relapses occurred more than 3 years after trans-
plantation. Thirty-three of the 37 patients (89.2%)
who relapsed within 3 years (early) died, compared to
7 of 27 (25.9%) of those who relapsed beyond 3 years
(late). (One patient relapsed 20 years following trans-
plantation after data analysis was completed.) Death
occurred less frequently (P \ .001) and the interval
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Figure 2. LFS of subjects who survived free of disease 3 years following
transplantation.
Biol Blood Marrow Transplant 15:851-855, 2009 853Late failure after transplantation for CMLfrom relapse to death was longer (P 5 .01) in patients
who relapsed late compared to those who relapsed
early. The estimated cumulative incidence of late re-
lapse for those patients who were alive and leukemia-
free at 3 years is 22.8% (95% CI: 15.6%-32.6%); late
relapse occurred in 32.5% of advanced phase and
21.4% of CP patients.
Survival and LFS for Patients Alive and
Leukemia-Free at 3 Years
This report focuses on late (beyond 3 years) events
after transplantation. Of the 182 patients (54.3% of
those who underwent transplantation) alive and leuke-
mia-free at 3 years, the estimated probability of 18-year
OS is 77.0% (95% CI: 65.3%-83.6%) and of 18-year
LFS is 61.9% (95% CI: 52.1%-70.3%) (Figure 2).
The annual risk of failure (because of relapse or
NRM) declined only very gradually beyond 3 years
(Figure 3).
For 153 CP patients who were leukemia-free survi-
vors at 3 years, the estimated probability of 18-year OS
is 83.3% (95% CI: 75.0%-89.0%) and the18-year
estimated probability of LFS 66.9% (95% CI:
56.1%-75.6%). The incidence of failure beyond 3
years remained significantly higher for patients who
had advanced (accelerated or blastic) phase disease at
transplantation compared to those in CP (P 5 .001).
Deaths Beyond 3 Years
Thirty-six patients who were alive and leukemia-
free at 3 years died subsequently. The primary causes
of death were cGVHD in 11, relapse in 7, new malig-
nancy in 6, organ failure in 6 (pulmonary in 4), infec-
tion in 2, stroke in 1, accidental in 1, and unknown
in 2. The cumulative incidence of developing a new
malignancy was 10.4% (95% CI: 5.6%-19.1%) at 15
years. Five patients developed squamous cell and 2
basal cell skin carcinomas (SCC, BCC); 1 each devel-
oped Ewing sarcoma, colon cancer, endometrial carci-
noma, cervical carcinoma, and a myeloproliferative
disorder.0.00
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Figure 1. Smoothed hazard of relapse (______) including 95% CIs
(______).Late NRM
The estimated cumulative incidence of late NRM is
18.1% (95% CI: 12.8%-24.5%), 40.6% in advanced
phase patients, and 14.0% in CP patients (P 5 .006).
The risk of NRM fell gradually beyond 3 years.Prognostic Factors
Age, sex, disease phase, interval from diagnosis to
transplantation, aGVHD, and cGVHD were evaluated
in univariate analysis; results for all patients who survived
leukemia-free at 3 years are presented in Table 2.
Multivariate analysis demonstrated that only
advanced disease phase (hazard ratio [HR] 2.75, P 5
.001) and older age (HR 1.39, P 5 .032) were associ-
ated with significantly diminished LFS and OS (HR
5 3.86, P\ .001; HR 1.54, P 5 .024, respectively)
of patients alive and leukemia-free at 3 years. Although
aGVHD (P5 .005) and longer interval from diagnosis
to transplantation (P\ .001) significantly influenced
survival from day zero, they did not significantly influ-
ence survival of patients alive and leukemia-free at 3
years. cGVHD was associated with a significantly
lower incidence of late relapse (HR 5 .30, P 5 .002),
but not survival or LFS. Advanced disease phase was
associated with a significantly increased rate of late
relapse (HR 2.50, P 5 .039) and of late NRM (HR0.00
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Figure 3. Smoothed hazard of failure (______) including 95% CIs
(______).
Table 2. LFS Univariate Cox Regression for the Entire
Dataset for Those Who Survived 3 Years without Disease
Variable
Hazard
Ratio P-Value 95%
Confidence
Interval
Acute GVHD* 1.28 0.406 0.72 2.29
Chronic GVHD† .75 0.353 0.42 1.37
Advanced phase‡ 2.47 0.003 1.35 4.53
Male sex§ 1.32 0.317 0.76 2.30
Age¶ 1.32 0.085 0.96 1.80
Interval from diagnosis
to transplantationt
1.20 0.285 0.86 1.69
GRHD indicates graft-versus-host disease; LFS, leukemia-free survival.
*Referent group is no aGVHD.
†Referent group is no cGVHD.
‡Referent group is chronic phase.
§Referent group is female.
¶Hazard ratio is for 10-year increase in age.
tHazard ratio is for a 1 unit increase in the natural log of diagnosis to
treatment time.
854 Biol Blood Marrow Transplant 15:851-855, 2009E. A. Copelan et al.3.18, P 5 .008). Older age (HR 1.72, P 5 .015), was
also associated with late NRM.
In multivariate analyses of CP patients alive and
free of leukemia at 3 years, none of the variables
included in this model were significantly predictive
of survival or LFS. cGVHD was associated with
a significantly lower incidence of late relapse (HR
.29, P 5 .004), but not survival or LFS.DISCUSSION
This study provides the longest published median
follow-up of a large cohort of patients who underwent
allogeneic BMT for CML at multiple institutions. The
large number of patients and institutions ensures its
broad applicability for patients undergoing allogeneic
BMT with the Bu/Cy2 regimen.
This report focuses on late events in patients alive
and leukemia-free 3 years following transplantation,
a group for whom transplantation is commonly re-
garded as having been successful. Approximately 4 of
every 5 such patients are estimated to be survivors at
18 years. Studies with less extended follow-up [1-6]
and a remarkably low incidence of late relapse in 1
study with extended follow up [9] have led clinicians
to infer that an overwhelming majority of patients alive
and leukemia-free 3 years following transplantation
are cured. The present study demonstrates a substan-
tial incidence of late relapse and shows unequivocally
that 3 or even 5 year relapse-free survival following
transplantation for CML is not equivalent to cure.
Nearly 2 of every 5 patients (1 in 3 of those trans-
planted with CP disease) who are alive and leukemia-
free at 3 years will die or relapse over the next 15 years.
Although expected mortality (deaths in an age-
matched general population) may account in part for
the absence of a plateau in mortality, such comparisonsin other studies [5,6] and the transplant-related nature
of many of the causes of late death in this cohort indi-
cate that these patients are at higher risk of death than
the general population. These data should ideally be
compared to a nontransplant treatment cohort of
CML patients for which mature data, unfortunately,
does not exist. The study patients, with a median age
of 37 years at transplantation, have a prolonged excess
risk of mortality and a persistent risk of relapse. There
is no plateau in LFS over the extended follow-up of
this study. Furthermore, the excess risk of failure for
patients with accelerated or blastic disease continues
beyond 3 years and extended LFS occurred in only
10% of advanced phase patients.
Similar to other reports [7], late relapse of CML
affected subsequent survival significantly less than
early relapse. Nearly all patients who relapsed within
3 years, but only one-fourth of those relapsing
beyond 3 years, died. The disparity suggests a biologic
difference in the cells responsible for relapse, similar to
that identified in acute lymphoblastic leukemia (ALL),
where early relapse following standard chemotherapy
appears to result from resistant, proliferative malig-
nant clones, whereas late relapse occurs because of
secondary events in leukemia stem cells [13].
It has been suggested that ‘‘current LFS’’ be re-
ported following transplantation in CML to recog-
nize patients who achieve sustained remissions and
prolonged survival following relapse [8], as occurs
commonly following imatinib and/or donor lympho-
cyte infusions (DLI) [14]. A substantial portion of the
present study predated molecular monitoring and
early detection and modern treatment of early re-
lapse. Although it will not improve LFS, monitoring
and early treatment of relapse will improve rates of
‘‘current LFS’’ and OS relative to the results reported
here. In addition, improved supportive care has led to
better survival in patients who undergo transplanta-
tion now compared to those in this study. Dose ad-
justment of Bu based on plasma levels improves
results [4] and i.v. administration of Bu appears safer
than oral administration [15], although its long-term
benefit is not proved. Although Bu/Cy2 appears to be
at least as safe and effective as radiation-based prepar-
ative therapy [2,3,11], the present data cannot exclude
the possibility that there is a higher late relapse rate
with Bu than with total body irradiation (TBI).
This analysis shows that only 3 of every 5 patients
who are alive and relapse-free 3 years following an allo-
transplantation for CML are alive and free of relapse
another 15 years later and potentially cured. Late fail-
ure because of relapse or NRM is common. Although
improvements in preparative regimens and posttrans-
plant care result in better outcomes, the present study
demonstrates that no plateau in LFS occurs following
allo-transplantation, and cure is less common than is
generally thought.
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